GABAA receptor-binding protein promotes sensitivity to apoptosis induced by chemotherapeutic agents

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1807-1814

  Rho, Seung Bae ^a   Byun, Hyun Jung ^a   Kim, Boh Ram ^a   Kim, Ik Sun ^a   Lee, Jeong Heon ^b   Yoo, Richard ^c   Park, Sung Taek ^d   Park, Sung Ho ^d  

^a National Cancer Center   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Hallym University   (South Korea)

Author keywords

Cell cycle; Chemotherapeutic agent; GABARBP; Pro apoptotic activity; Tumorigenesis

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; GAMMA AMINOBUTYRATE TYPE A RECEPTOR BINDING PROTEIN; LUCIFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; GABARAP PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ULTRAVIOLET IRRADIATION; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS;

EID: 84876001576     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1866     Document Type: Article

References (61)

1. Jamieson ER and Lippard SJ: Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
2. Charalabopoulos K, Karkabounas S, Ioachim E, et al: Antitumour and toxic effects on Wistar rats of two new platinum complexes. Eur J Clin Invest 32: 129-133, 2002. (Pubitemid 36232734)
3. Covens A, Carey M, Bryson P, et al: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III or IV epithelial ovarian cancer. Gynecol Oncol 85: 71-80, 2002. (Pubitemid 34304013)
4. Androulakis N, Syrigos K, Polyzos A, et al: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 23: 9-12, 2005. (Pubitemid 40344194)
5. Polyzos A, Syrigos K, Stergiou J, et al: Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Cancer Chemother Pharmacol 55: 466-470, 2005. (Pubitemid 40568977)
6. Androulakis N, Aravantinos G, Syrigos K, et al: Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology 70: 280-284, 2006. (Pubitemid 44670168)
7. Karapanagiotou EM, Boura PG, Papamichalis G, et al: Carboplatin- pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res 29: 4297-4301, 2009.
8. Syrigos KN, Karachalios D, Karapanagiotou EM, et al: Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev 35: 237-245, 2009.
9. Charpidou A, Tsagouli S, Tsimpoukis S, et al: Triplet combination of carboplatin, irinotecan and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study. Anticancer Drugs 21: 651-655, 2010.
10. Bhoola S and Hoskins WJ: Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107: 1399-1410, 2006. (Pubitemid 44336908)
11. Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997. (Pubitemid 27282064)
12. Leith C: Multidrug resistance in leukemia. Curr Opin Hematol 5: 287-291, 1998. (Pubitemid 29015649)
13. Szakács G, Jakab K, Antal F and Sarkadi B: Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 4: 251-257, 1998. (Pubitemid 29081094)
14. Ohsumi Y: Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol 2: 211-216, 2001. (Pubitemid 33675746)
15. Mizushima N: The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ 12: 1535-1541, 2005. (Pubitemid 41553990)
16. Zhu JH, Horbinski C, Guo F, et al: Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4- phenylpyridiniuminduced cell death. Am J Pathol 170: 75-86, 2007. (Pubitemid 47339191)
17. Wang H, Bedford FK, Brandon NJ, Moss SJ and Olsen RW: GABA(A)-receptor-associated protein links GABA(A) receptors and the cytoskeleton. Nature 397: 69-72, 1999. (Pubitemid 29038250)
18. Wang H and Olsen RW: Binding of the GABA(A) receptor-associated protein (GABARAP) to microtubules and microfilaments suggests involvement of the cytoskeleton in GABARAPGABA(A) receptor interaction. J Neurochem 75: 644-655, 2000. (Pubitemid 30485445)
19. Kneussel M, Haverkamp S, Fuhrmann JC, et al: The gamma-aminobutyric acid type A receptor (GABAAR)-associated protein GABARAP interacts with gephyrin but is not involved in receptor anchoring at the synapse. Proc Natl Acad Sci USA 97: 8594-8599, 2000. (Pubitemid 30639718)
20. Tretter V, Jacob TC, Mukherjee J, et al: The clustering of GABA(A) receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J Neurosci 28: 1356-1365, 2008. (Pubitemid 351231519)
21. Mohrlüder J, Hoffmann Y, Stangler T, Hänel K and Willbold D: Identification of clathrin heavy chain as a direct interaction partner for the gamma-aminobutyric acid type A receptor associated protein. Biochemistry 46: 14537-14543, 2007. (Pubitemid 350276359)
22. Kanematsu T, Jang I-S, Yamaguchi T, et al: Role of the PLC-related, catalytically inactive protein p130 in GABA(A) receptor function. EMBO J 21: 1004-1011, 2002. (Pubitemid 34206173)
23. Green F, O'Hare T, Blackwell A and Enns CA: Association of human transferrin receptor with GABARAP. FEBS Lett 518: 101-106, 2002. (Pubitemid 34454972)
24. Okazaki N, Yan J, Yuasa S, et al: Interaction of the Unc-51-like kinase and microtubule-associated protein light chain 3 related proteins in the brain: possible role of vesicular transport in axonal elongation. Brain Res Mol Brain Res 85: 1-12, 2000. (Pubitemid 32056233)
25. Wu M, Yin G, Zhao X, et al: Human RAB24, interestingly and predominantly distributed in the nuclei of COS-7 cells, is colocalized with cyclophilin A and GABARAP. Int J Mol Med 17: 749-754, 2006.
26. Lee JH, Rho SB and Chun T: GABAA receptor-associated protein (GABARAP) induces apoptosis by interacting with DEAD (Asp-Glu-Ala-Asp/His) box polypeptide 47 (DDX47). Biotechnol Lett 27: 623-628, 2005. (Pubitemid 40865672)
27. Kittler JT, Arancibia-Carcamo IL and Moss SJ: Association of GRIP1 with a GABA(A) receptor associated protein suggests a role for GRIP1 at inhibitory synapses. Biochem Pharmacol 68: 1649-1654, 2004. (Pubitemid 39286469)
28. Mohrlüder J, Stangler T, Hoffmann Y, et al: Identification of calreticulin as a ligand of GABARAP by phage display screening of a peptide library. FEBS J 274: 5543-5555, 2007. (Pubitemid 47622066)
29. Cook JL, Re RN, deHaro DL, et al: The trafficking protein GABARAP binds to and enhances plasma membrane expression and function of the angiotensin II type 1 receptor. Circ Res 102: 1539-1547, 2008.
30. Laínez S, Valente P, Ontoria-Oviedo I, et al: GABAA receptor associated protein (GABARAP) modulates TRPV1 expression and channel function and desensitization. FASEB J 24: 1958-1970, 2010.
31. Schwarten M, Mohrlüder J, Ma P, et al: Nix directly binds to GABARAP: a possible crosstalk between apoptosis and autophagy. Autophagy 5: 690-698, 2009.
32. Alam J, Deharo D, Redding KM, Re RN and Cook JL: C-terminal processing of GABARAP is not required for trafficking of the angiotensin II type 1A receptor. Regul Pept 159: 78-86, 2010.
33. Klebig C, Seitz S, Arnold W, et al: Characterization of γ-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer. Cancer Res 65: 394-400, 2005.
34. Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL and Vasko V: GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res 15: 645-650, 2009.
35. Miao Y, Zhang Y, Chen Y, Chen L and Wang F: GABARAP is overexpressed in colorectal carcinoma and correlates with shortened patient survival. Hepatogastroenterology 57: 257-261, 2010.
36. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002. (Pubitemid 37328783)
37. Oren M: Decision making by p53: life, death and cancer. Cell Death Differ 10: 431-442, 2003. (Pubitemid 36626355)
38. Steele RJ and Lane DP: P53 in cancer: a paradigm for modern management of cancer. Surgeon 3: 197-205, 2005. (Pubitemid 40932719)
39. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994. (Pubitemid 24138678)
40. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
41. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34: 9-19, 1997. (Pubitemid 28032415)
42. Antonsson B and Martinou JC: The Bcl-2 protein family. Exp Cell Res 256: 50-57, 2000. (Pubitemid 30211166)
43. Bentires-Alj M, Dejardin E, Viatour P, et al: Inhibition of the NF-kappaB transcription factor increases Bax expression in cancer cell lines. Oncogene 20: 2805-2813, 2001. (Pubitemid 32549837)
44. Heckman CA, Mehew JW and Boxer LM: NF-kappaB activates Bcl-2 expression in t(14:18) lymphoma cells. Oncogene 21: 3898-3908, 2002. (Pubitemid 34620858)
45. Khwaja A: Akt is more than just a Bad kinase. Nature 401: 33-34, 1999.
46. McComick F: Cancer: survival pathways meet their end. Nature 428: 267-269, 2004.
47. Westfall SD: Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 11: 1764-1769, 2005.
48. Shih KK and Chi DS: Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21: 75-80, 2010.
49. Altaha R, Reed E and Abraham J: Breast and ovarian cancer genetics and prevention. W V Med J 99: 187-191, 2003.
50. Wang C, Horiuchi A, Imai T, et al: Expression of BRCA1 protein in benign, borderline and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202: 215-223, 2004. (Pubitemid 38208659)
51. Rho SB, Kim BR and Kang S: A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 120: 121-127, 2011.
52. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
53. Kanematsu T, Mizokami A, Watanabe K and Hirata M: Regulation of GABAA-receptor surface expression with special reference to the involvement of GABARAP (GABAA receptor-associated protein) and PRIP (phospholipase C-related, but catalytically inactive protein). J Pharmacol Sci 104: 285-292, 2007. (Pubitemid 47378415)
54. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002. (Pubitemid 34161136)
55. Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 23: 367-387, 2004. (Pubitemid 38881819)
56. Guertin DA and Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361, 2005. (Pubitemid 41080576)
57. Yuan ZQ, Sun N, Feldman RI, et al: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324-2330, 2000. (Pubitemid 30307208)
58. Bjornsti MA and Houghton PJ: The mTOR pathways: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004. (Pubitemid 38579480)
59. Bjornsti MA and Houghton PJ: Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5: 519-523, 2004. (Pubitemid 38748913)
60. Suvasini R and Somasundaram K: Essential role of PI3K-kinase pathway in p53-mediated transcription: implications in cancer chemotherapy. Oncogene 29: 3605-3618, 2010.
61. Tonini T, Gabellini C, Bagella L, et al: pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res 10: 8085-8093, 2004. (Pubitemid 39587550)